Clinical Trial Update: A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating QL2107 plus chemotherapy versus pembrolizumab (Keytruda) in non-small cell lung cancer is currently recruiting. Sponsored by Qilu Pharm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• QL2107

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: NSCLC | Phase 3 | Status: RECRUITING